RYTM Insider Trading Activity and SEC Form 4 Filings
RYTM insider trading summary
Over the past 12 months, insiders at Rhythm Pharmaceuticals, Inc. (RYTM) reported 50 sales worth $38.6M by 9 insiders and no open-market purchases on SEC Form 4. Net insider selling was $38.6M.
Latest RYTM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 14, 2026 | David P Meeker | President and CEO | Sell | $655K (6,439 @ $101.75) |
| Sep 14, 2026 | David P Meeker | President and CEO | Sell | $242K (2,300 @ $105.19) |
| Sep 14, 2026 | David P Meeker | President and CEO | Sell | $190K (1,817 @ $104.55) |
| Sep 14, 2026 | David P Meeker | President and CEO | Sell | $900K (8,698 @ $103.43) |
| Sep 14, 2026 | David P Meeker | President and CEO | Sell | $3.1M (30,746 @ $102.35) |
| Aug 31, 2026 | Hunter C Smith | Chief Financial Officer | Sell | $3.0M (28,188 @ $106.20) |
| Aug 31, 2026 | Hunter C Smith | Chief Financial Officer | Sell | $1.2M (11,514 @ $105.37) |
| Aug 31, 2026 | Hunter C Smith | Chief Financial Officer | Sell | $2.4M (23,072 @ $104.59) |
| Aug 13, 2026 | Alastair Garfield | Chief Scientific Officer | Sell | $233K (2,007 @ $116.11) |
| Aug 13, 2026 | Alastair Garfield | Chief Scientific Officer | Sell | $182K (1,556 @ $117.08) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.